EGFR and non-small cell lung carcinoma: Predominantly comprising exon 19 deletions or L858R mutations in exon 21, these EGFR alterations serve as key targets for EGFR tyrosine kinase inhibitors (TKIs)—a therapeutic intervention that significantly enhances the prognosis of inoperable NSCLC patients [3,4].